Dr. Ashwani Kumar Agarwal, MD

Dr. Agarwal practices at Texas Oncology PA in Corsicana, Texas.

Dr. Agarwal's NPI, 1801837497, was assigned on June 8, 2006. Dr. Agarwal holds Texas license K3052.

Dr. Agarwal's primary practice is Texas Oncology PA, at 301 Hospital Dr, Corsicana, TX 75110 in Navarro County. The practice phone is (972) 997-8000.

Dr. Agarwal's primary practice is Texas Oncology PA in Corsicana, Texas. Dr. Agarwal is also affiliated with Navarro Regional Hospital. The medical group on file is Texas Oncology. Dmand AI also links Dr. Agarwal to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Agarwal practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Agarwal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Agarwal is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Agarwal's licenses on file in 4 states: Texas, California, Illinois and Wisconsin.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Agarwal treats.

CMS data shows 34,379 Medicare services from Dr. Agarwal across 37 procedure codes in 2024, for 471 Medicare patients. Medicare paid $326,202 for them. Every service was in an office.

CMS counts 471 Medicare patients who saw Dr. Agarwal in 2024. The largest group is 75 to 84, with 212 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Agarwal's median patient age at 72, with 60% women.

In 2024, Dr. Agarwal wrote 1,501 Medicare Part D claims for 255 patients. 76% of them were for generic drugs. CMS names the drug for 1,270 of them, across 35 drugs with 11 or more claims each, at $2,562,534 in total drug cost. In 2023, CMS named 1,201 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Agarwal for performance year 2024, reported through an alternative payment model (APM). Dr. Agarwal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Agarwal as offering telehealth.

Dmand AI links Dr. Agarwal to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases.

CMS Open Payments shows 1,695 general payments to Dr. Agarwal from 103 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Rigel Pharmaceuticals, Inc. paid the most, $75,175.

Dmand AI lists 1 award for Dr. Agarwal, most recently CMS Stage 1 2012 in 2012.

Dr. Agarwal is in network with 23 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.